An Observational Study on Immune-related Disorders and Their Treatment Response in Ayurveda- Case Series

K. Pradeep *

Department of Physiology /Kriya Sharira, Government Ayurveda Medical College, Tripunithura, India.

M. Abhilash

Department of Physiology /Kriya Sharira, Government Ayurveda Medical College, Tripunithura, India.

M. A. Reshma

Department of Physiology /Kriya Sharira, Government Ayurveda Medical College, Tripunithura, India.

Bindu K. Viswambaran

Department of Physiology /Kriya Sharira, Government Ayurveda Medical College, Tripunithura, India.

*Author to whom correspondence should be addressed.


Abstract

Immune-related disorders are common health problems in the world. Based on the principal immunologic mechanism they are classified into four types. One of the four types includes immediate hypersensitivity which is an IgE antibody and mast cell-mediated reaction. Ayurvedic treatments have sometimes delivered good results in the treatment of these disorders. This work is a humble effort to streamline Immune-related diseases in the settings of Govt Ayurveda Medical College, Tripunithura, Kerala, India. In this case series study patients with allergic rhinitis and urticaria were selected. Their symptoms and blood parameters were assessed both before and after the Ayurvedic treatment for one month. In both allergic rhinitis and urticaria, there was a significant reduction in the symptoms. In the case of blood investigations, only IgE showed a significant change in allergic rhinitis. Even though Ayurvedic immunology has a strong potential to treat allergic disorders with its pro-nature individualized holistic approach to make significant changes in immune parameters administration of rejuvenators for more than one month is very essential.

Keywords: Urticaria, allergic rhinitis, immune-related disorders and Ayurveda


How to Cite

Pradeep, K., Abhilash, M., Reshma, M. A. and Viswambaran, B. K. (2021) “An Observational Study on Immune-related Disorders and Their Treatment Response in Ayurveda- Case Series”, Journal of Pharmaceutical Research International, 33(37A), pp. 199–207. doi: 10.9734/jpri/2021/v33i37A31999.